WO1996004897A1 - Verwendung von selegilin zur behandlung von epileptischen erkrankungen - Google Patents
Verwendung von selegilin zur behandlung von epileptischen erkrankungenInfo
- Publication number
- WO1996004897A1 WO1996004897A1 PCT/DE1995/000981 DE9500981W WO9604897A1 WO 1996004897 A1 WO1996004897 A1 WO 1996004897A1 DE 9500981 W DE9500981 W DE 9500981W WO 9604897 A1 WO9604897 A1 WO 9604897A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- selegiline
- treatment
- epileptic
- effect
- selegilin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Definitions
- Selegiline is known to be a type B monoamine oxidase blocker. This enzyme breaks down monoaminergic neurotransmitters (especially dopamine) in glial cells, which leads to the end of the effects of dopamine. By blocking the enzyme, the level of dopamine in the brain is raised. Because of this effect, selegiline is used as an additional treatment together with levodopa in the therapy of Parkinson's disease (for example under the trademark Deprenyl in the trade).
- WO 92 17 169 A1 describes a neuroprotective effect with a mechanism of action which has not yet been defined. It is therefore proposed for use as a neuroprotective agent (prevention of nerve cell loss in diseases of the CNS, in particular Parkinson's disease, brain trauma and spinal cord trauma).
- a number of anticonvulsants are on the market for the treatment of epilepsy. Phenytoin and carbamazepine should be mentioned as important representatives. The anticonvulsants used so far for therapy lead to the suppression of the cramp, but have no effect on the development of the actual epileptic focus.
- the object of the present invention is to provide medicaments with good anticonvulsant and antiepileptogenic effects.
- the cramp threshold is considered the most important feature of an anticonvulsant effect.
- Epilepsy is a threshold phenomenon and cramp is triggered in humans by crossing the threshold through endogenous or exogenous stimuli.
- Medicines of the first choice for the treatment of epilepsy increase the threshold, drugs of the second choice often do not influence the threshold but only reduce the seizure severity of the individual attack.
- An effect of selegiline on the threshold could also be demonstrated in a classic epilepsy model, the maximum electric shock.
- selegiline shows an effect similar to that of drugs of first choice.
- selegiline is also able to slow the development of the focus of epilepsy and thus to slow the progression of the disease.
- the D shape is ineffective. It loosens in cans without the L-shape
- an epileptic focus is induced by repeated, very weak stimulation from a brain area of the rat via deep electrodes.
- This hearth is permanent and animals that are fully encircled can be described as epileptic.
- Anticonvulsants can now be examined in this model. If they are given fully wrapped animals and a spasm is triggered, the threshold for triggering the spasm may be increased (it must be stimulated more strongly to trigger a spasm) and the spasm triggered nevertheless can be weaker.
- this model can also be used to investigate drugs that - regardless of their effect against the induced spasm - suppress the development of the epileptic focus.
- the anticonvulsant effect is independent of the effect against the development of the focus of epilepsy.
- the duration of epileptic discharges that can be triggered in fully-fed animals is significantly shorter than in feces.
- Selegiline can thus be used as a highly specific active drug for the treatment of epileptic diseases.
- the compounds can be converted in a known manner into the customary formulations, such as tablets, capsules, dragées, pills, granules, syrups, emulsions, suspensions and solutions, using inert, non-toxic, pharmaceutically suitable excipients or solvents.
- the daily dose of selegiline should be 5 - 20 mg when administered orally or partially.
Abstract
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU9700405A HU223529B1 (hu) | 1994-08-11 | 1995-07-27 | Szelegilin alkalmazása epilepsziás betegségek kezelésére használható gyógyszerkészítmények előállítására |
EE9700068A EE04176B1 (et) | 1994-08-11 | 1995-07-27 | Selegiliini kasutamine epileptiliste haiguste raviks mõeldud ravimpreparaatide valmistamiseks |
CZ97407A CZ285681B6 (cs) | 1994-08-11 | 1995-07-27 | Použití selegilinu pro výrobu farmacetického prostředku k ošetřování epileptických onemocnění a farmaceutický prostředek, který selegilin obsahuje |
AU29760/95A AU691316B2 (en) | 1994-08-11 | 1995-07-27 | Use of selegilin in the treatment of epileptic conditions |
DK95925732T DK0774961T3 (da) | 1994-08-11 | 1995-07-27 | Anvendelse af selegilin til behandling af epileptiske lidelser |
AT95925732T ATE239458T1 (de) | 1994-08-11 | 1995-07-27 | Verwendung von selegilin zur behandlung von epileptischen erkrankungen |
US08/776,931 US5952388A (en) | 1994-08-11 | 1995-07-27 | Use of selegiline for the treatment of epileptic disorders |
SK199-97A SK283205B6 (sk) | 1994-08-11 | 1995-07-27 | Použitie selegilínu na ošetrovanie epileptických ochorení |
MXPA/A/1997/001031A MXPA97001031A (en) | 1994-08-11 | 1995-07-27 | Utilization of selegiline for the treatment of epilepti diseases |
CA002197176A CA2197176C (en) | 1994-08-11 | 1995-07-27 | Use of selegiline for the treatment of epileptic disorders |
PL31829295A PL188040B1 (pl) | 1994-08-11 | 1995-07-27 | Zastosowanie selegiliny |
EP95925732A EP0774961B1 (de) | 1994-08-11 | 1995-07-27 | Verwendung von selegilin zur behandlung von epileptischen erkrankungen |
BR9508531A BR9508531A (pt) | 1994-08-11 | 1995-07-27 | Emprego de selegilin para o tratamento de doença epilépticas |
JP50690596A JP3922307B2 (ja) | 1994-08-11 | 1995-07-27 | てんかん性疾患の治療のためのセレギリンの使用 |
DE59510674T DE59510674D1 (de) | 1994-08-11 | 1995-07-27 | Verwendung von selegilin zur behandlung von epileptischen erkrankungen |
NO19970607A NO314684B1 (no) | 1994-08-11 | 1997-02-10 | Anvendelse av selegilin til fremstilling av farmasöytiske preparater for behandling av epileptiske tilstander |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP4428444.6 | 1994-08-11 | ||
DE4428444A DE4428444A1 (de) | 1994-08-11 | 1994-08-11 | Verwendung von Selegilin zur Behandlung von epileptischen Erkrankungen |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996004897A1 true WO1996004897A1 (de) | 1996-02-22 |
Family
ID=6525440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE1995/000981 WO1996004897A1 (de) | 1994-08-11 | 1995-07-27 | Verwendung von selegilin zur behandlung von epileptischen erkrankungen |
Country Status (23)
Country | Link |
---|---|
US (1) | US5952388A (de) |
EP (1) | EP0774961B1 (de) |
JP (1) | JP3922307B2 (de) |
CN (1) | CN1081918C (de) |
AT (1) | ATE239458T1 (de) |
AU (1) | AU691316B2 (de) |
BR (1) | BR9508531A (de) |
CA (1) | CA2197176C (de) |
CZ (1) | CZ285681B6 (de) |
DE (2) | DE4428444A1 (de) |
DK (1) | DK0774961T3 (de) |
EE (1) | EE04176B1 (de) |
ES (1) | ES2199252T3 (de) |
HU (1) | HU223529B1 (de) |
MY (1) | MY116362A (de) |
NO (1) | NO314684B1 (de) |
PL (1) | PL188040B1 (de) |
PT (1) | PT774961E (de) |
RU (1) | RU2155584C2 (de) |
SK (1) | SK283205B6 (de) |
TR (1) | TR199500984A2 (de) |
TW (1) | TW448044B (de) |
WO (1) | WO1996004897A1 (de) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19630035A1 (de) * | 1996-07-25 | 1998-01-29 | Asta Medica Ag | Tramadol Multiple Unit Formulierungen |
DE19716905C1 (de) * | 1997-04-22 | 1998-08-27 | Iip Inst Fuer Ind Pharmazie Fo | Stabile, wäßrige Lösung auf der Grundlage von Selegilin und Vorrichtung zu ihrer Verabreichung |
DE19743323C2 (de) * | 1997-09-30 | 2000-05-25 | Iip Inst Fuer Ind Pharmazie Fo | Feste Arzneimittelzusammensetzung auf der Grundlage von Selegilin |
ATE427745T1 (de) | 2001-11-05 | 2009-04-15 | Krele Pharmaceuticals Llc | Zusammensetzungen und verfahren zur erhíhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus |
GB201715919D0 (en) * | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992017169A1 (en) * | 1991-04-04 | 1992-10-15 | The University Of Toronto Innovations Foundation | Use of deprenyl to maintain, prevent loss, or recover nerve cell function |
EP0614663A1 (de) * | 1993-03-09 | 1994-09-14 | Sanofi Sante Nutrition Animale | Pharmazeutische Zusammensetzung, die ein allgemeines Anästhetikum ung Selegilin enthält |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5192808A (en) * | 1990-08-31 | 1993-03-09 | Deprenyl Animal Health, Inc. | Therapeutic effect of L-deprenyl in the management of pituitary-dependent hyperadrenocorticism (cushing's disease) |
US5462740A (en) * | 1993-09-17 | 1995-10-31 | Athena Neurosciences, Inc. | Rectally-administered, epileptic-seizure-inhibiting composition |
-
1994
- 1994-08-11 DE DE4428444A patent/DE4428444A1/de not_active Withdrawn
-
1995
- 1995-07-17 TW TW084107378A patent/TW448044B/zh not_active IP Right Cessation
- 1995-07-27 CZ CZ97407A patent/CZ285681B6/cs not_active IP Right Cessation
- 1995-07-27 CN CN95194569A patent/CN1081918C/zh not_active Expired - Fee Related
- 1995-07-27 DK DK95925732T patent/DK0774961T3/da active
- 1995-07-27 BR BR9508531A patent/BR9508531A/pt not_active Application Discontinuation
- 1995-07-27 SK SK199-97A patent/SK283205B6/sk not_active IP Right Cessation
- 1995-07-27 EP EP95925732A patent/EP0774961B1/de not_active Expired - Lifetime
- 1995-07-27 JP JP50690596A patent/JP3922307B2/ja not_active Expired - Fee Related
- 1995-07-27 WO PCT/DE1995/000981 patent/WO1996004897A1/de active IP Right Grant
- 1995-07-27 DE DE59510674T patent/DE59510674D1/de not_active Expired - Fee Related
- 1995-07-27 ES ES95925732T patent/ES2199252T3/es not_active Expired - Lifetime
- 1995-07-27 PT PT95925732T patent/PT774961E/pt unknown
- 1995-07-27 RU RU97104062/14A patent/RU2155584C2/ru not_active IP Right Cessation
- 1995-07-27 EE EE9700068A patent/EE04176B1/xx not_active IP Right Cessation
- 1995-07-27 HU HU9700405A patent/HU223529B1/hu not_active IP Right Cessation
- 1995-07-27 PL PL31829295A patent/PL188040B1/pl not_active IP Right Cessation
- 1995-07-27 CA CA002197176A patent/CA2197176C/en not_active Expired - Fee Related
- 1995-07-27 AU AU29760/95A patent/AU691316B2/en not_active Ceased
- 1995-07-27 US US08/776,931 patent/US5952388A/en not_active Expired - Fee Related
- 1995-07-27 AT AT95925732T patent/ATE239458T1/de not_active IP Right Cessation
- 1995-07-31 MY MYPI95002228A patent/MY116362A/en unknown
- 1995-08-09 TR TR95/00984A patent/TR199500984A2/xx unknown
-
1997
- 1997-02-10 NO NO19970607A patent/NO314684B1/no not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992017169A1 (en) * | 1991-04-04 | 1992-10-15 | The University Of Toronto Innovations Foundation | Use of deprenyl to maintain, prevent loss, or recover nerve cell function |
EP0614663A1 (de) * | 1993-03-09 | 1994-09-14 | Sanofi Sante Nutrition Animale | Pharmazeutische Zusammensetzung, die ein allgemeines Anästhetikum ung Selegilin enthält |
Non-Patent Citations (3)
Title |
---|
LÖSCHER, W. ET AL: "Anticonvulsant and antiepileptogenic effect of l-deprenyl (selegiline) in the kindling model of epilepsy", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 274, no. 1, 2 March 1995 (1995-03-02), pages 307 - 314 * |
MUKHOPADHYAY, M. ET AL: "Neuropharmacological studies on selective monoamine oxidase A and B inhibitors", INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY, vol. 25, no. 11, pages 761 - 770 * |
SPARKS, D.L. ET AL: "Combined inhibition of serotonin uptake and oxidative deamination attenuates audiogenic seizures in DBA/2J mice", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOUR, vol. 23, no. 5, pages 753 - 757 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0857065B1 (de) | Verwendung von 2-amino-4-(4-fluorbenzylamino)-1-ethoxycarbonylaminobenzen zur prophylaxe und behandlung der folgen der akuten und chronischen zerebralen minderdurchblutung sowie neurodegenerativer erkrankungen | |
WO2001022953A2 (de) | Verwendung von retigabin zur behandlung von neuropathischen schmerzen | |
Woolverton et al. | Preference in rhesus monkeys given a choice between cocaine and d, l‐cathinone | |
WO2001015682A1 (de) | Pharmazeutische tramadolsalze | |
DE60218193T2 (de) | Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia | |
EP0774961B1 (de) | Verwendung von selegilin zur behandlung von epileptischen erkrankungen | |
DE69626816T2 (de) | Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren | |
DE60029463T2 (de) | Behandlung von dyskinesie | |
EP1513533A2 (de) | Pharmazeutische wirkstoffkombination sowie deren verwendung | |
DE69926794T2 (de) | Ponazuril zur behandlung von durch coccidia neurologischen und "abortigenic" verursachten erkrankungen | |
DE60028787T2 (de) | Methode zur behandlung von verletzungen des traumatisierten gehirns mit nicht-steroid entzündungshemmenden medikamenten | |
Haussmann et al. | Das nichtentzugsbedingte Delir. | |
DE2831728C2 (de) | Arzneimittel zur Behandlung von Kopfschmerzen | |
EP0493861B1 (de) | Nicotinamid-adenin-dinukleodid enthaltendes Antidepressionsmittel | |
EP2066314B1 (de) | Verwendung von theogallin zur behandlung von mentalen konzentrationsleistungsstörungen, depression und demenz | |
DE60107393T2 (de) | Verwendung von tramadol zur herstellung eines arzneimittels zur behandlung von funktionelle gastrointestinale krankenheiten | |
DE3719367A1 (de) | Verwendung von den stoffwechsel und/oder die struktureigenschaften von kollagen beeinflussenden wirksubstanzen in der kieferorthopaedie | |
US20200121644A1 (en) | Methods of treating sepsis with synaptic vesicle 2a and/or 2b binding chemical entities | |
CH710163A2 (de) | Bupropion zur Behandlung von Multipler Sklerose. | |
DE2916880A1 (de) | Arzneimittel mit sedativer und schlafinduzierender wirkung sowie dieses enthaltende pharmazeutische zubereitungen | |
Hudson | Effects of trifluoperazine on the central nervous system of the cat | |
DE19629976A1 (de) | Verwendung von 4-(p-Halogenphenyl)-3-morpholinopyrrol-2-carbonsäuremethylester zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen | |
MXPA97001031A (en) | Utilization of selegiline for the treatment of epilepti diseases | |
AT504700A1 (de) | Behandlung von angstzuständen | |
WO2008037415A1 (de) | Verwendung von theanin zur herstellung eines arzneimittels zur prophylaxe und behandlung von psychiatrischen störungen des zentralen nervensystems, insbesondere von depressionen und schmerzen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1997/001031 Country of ref document: MX Ref document number: 95194569.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN CZ EE FI HU JP KZ MX NO PL RU SK US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1995925732 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1997-407 Country of ref document: CZ Ref document number: 2197176 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 19997 Country of ref document: SK Ref document number: 08776931 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1995925732 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1997-407 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1997-407 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995925732 Country of ref document: EP |